Meeting
2022 ASCO Gastrointestinal Cancers Symposium
Durvalumab (MEDI 4736) with extended neoadjuvant regimens in rectal cancer: A randomized phase II trial (PRIME-RT).
Authors
Catherine Ruth Hanna
Beatson West of Scotland Cancer Centre, Glasgow, United Kingdom
Catherine Ruth Hanna , Sean Michael O'Cathail , Janet Graham , Mark P. Saunders , Leslie M. Samuel , Lynsey Devlin , Joanne Edwards , Noori Maka , Caroline Kelly , Laura Dempsey , Leia Jones , Liz-Anne Lewsley , Paula Morrison , Peter Atherton , Susan Dillon , Jacqueline Gourlay , Jonathan Platt , Ellie Tiplady , Richard Adams , Campbell SD Roxburgh
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Trials in Progress Poster Session
Session Title
Trials in Progress Poster Session C: Cancers of the Colon, Rectum, and Anus
Track
Colorectal Cancer,Anal Cancer
Sub Track
Translational Research
Clinical Trial Registration Number
NCT04621370
DOI
10.1200/JCO.2022.40.4_suppl.TPS231
Abstract #
TPS231
Poster Bd #
Online Only
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Gastrointestinal Cancers Symposium
Durvalumab (MEDI 4736) with extended neoadjuvant regimens in rectal cancer: A randomised phase II trial (PRIME-RT).
First Author: Campbell SD Roxburgh
Poster
2024 ASCO Gastrointestinal Cancers Symposium
Phase 2 study of trastuzumab deruxtecan as neoadjuvant treatment for HER2-positive gastric and gastroesophageal junction adenocarcinoma (EPOC2003).
First Author: Daisuke Takahari
Poster
2022 ASCO Gastrointestinal Cancers Symposium
Phase II study of durvalumab following neoadjuvant chemoRT in operable rectal cancer: NSABP FR-2.
First Author: Thomas J. George
Poster
2021 ASCO Annual Meeting
Phase II study of preoperative (PREOP) chemoradiotherapy (CTRT) plus avelumab (AVE) in patients (PTS) with locally advanced rectal cancer (LARC): The AVANA study.
First Author: Lisa Salvatore